These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 2733705)
1. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results. Coleman RJ; Lange KW; Quinn NP; Loper AE; Bondi JV; Hichens M; Stahl SM; Marsden CD Mov Disord; 1989; 4(2):129-38. PubMed ID: 2733705 [TBL] [Abstract][Full Text] [Related]
2. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease. Coleman RJ; Quinn NP; Traub M; Marsden CD J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963 [TBL] [Abstract][Full Text] [Related]
3. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation. Cedarbaum JM; Clark M; Toy LH; Green-Parsons A Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657 [TBL] [Abstract][Full Text] [Related]
4. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease. Weiner WJ; Factor SA; Sanchez-Ramos JR J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265 [TBL] [Abstract][Full Text] [Related]
6. Antiparkinsonian activity of a single oral dose of PHNO. Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120 [TBL] [Abstract][Full Text] [Related]
7. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Nomoto M; Stahl S; Jenner P; Marsden CD Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119 [TBL] [Abstract][Full Text] [Related]
8. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment. Zimmerman TR; Sage JI; Lang AE; Mark MH Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678 [TBL] [Abstract][Full Text] [Related]
9. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys. Rupniak NM; Tye SJ; Jennings CA; Loper AE; Bondi JV; Hichens M; Hand E; Iversen SD; Stahl SM Neurology; 1989 Mar; 39(3):329-35. PubMed ID: 2784549 [TBL] [Abstract][Full Text] [Related]
10. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660 [TBL] [Abstract][Full Text] [Related]
12. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease. Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362 [TBL] [Abstract][Full Text] [Related]
13. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. Metman LV; Hoff J; Mouradian MM; Chase TN Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216 [TBL] [Abstract][Full Text] [Related]
14. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys. Rosenzweig-Lipson S; Bergman J J Pharmacol Exp Ther; 1993 Jun; 265(3):1039-46. PubMed ID: 8099614 [TBL] [Abstract][Full Text] [Related]
15. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Chen JJ; Obering C Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444 [TBL] [Abstract][Full Text] [Related]
16. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047 [TBL] [Abstract][Full Text] [Related]
17. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Nutt JG; Carter JH; Lea ES; Woodward WR Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. Baas H; Harder S; Bürklin F; Demisch L; Fischer PA Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic experiences with an abeorphine derivative in Parkinson's disease. Birbamer G; Ransmayr G; Gerstenbrand F; Poewe W Adv Neurol; 1987; 45():591-2. PubMed ID: 3825736 [TBL] [Abstract][Full Text] [Related]
20. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Fabbrini G; Mouradian MM; Juncos JL; Schlegel J; Mohr E; Chase TN Ann Neurol; 1988 Sep; 24(3):366-71. PubMed ID: 3228270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]